96 Evaluation of hormone therapies in a panel of breast PDX models: Relevance of ER status on sensitivity to letrozole and tamoxifen

Wick, M.J.; Vaught, Teresa L.; Gamez, Lizette; Meade, Jonathan R.; Diaz, Abigail; Papadopoulos, K.; Rasco, Drew W.; Patnaik, Amita; Beeram, M.; Lang, Amy; Tolcher, A. W.

doi:10.1016/s0959-8049(14)70222-9

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the case of BC, ER, PR and HER2 expression analysis has been a routine clinical practice for years, and has made a significant contribution to the drug selection process and tumor response to adjuvant therapies ( 28 ). ER/PR expression status guides the selection of hormone therapies for BC ( 51 ) and HER2 expression status is a predictive marker for the response of patients with BC to trastuzumab ( 52 ). In the present study, low expression of TRIM28 was significantly correlated with improved RFS in the ER-positive, HER2-negative and PR-positive expression groups.…”

Section: Discussionmentioning

confidence: 99%

Bioinformatics analysis of the prognostic value of Tripartite Motif 28 in breast cancer

et al. 2017

View full text Add to dashboard Cite

Tripartite motif containing 28 (TRIM28) is a transcriptional regulator acting as an essential corepressor for Krüppel-associated box zinc finger domain-containing proteins in multiple tissue and cell types. An increasing number of studies have investigated the function of TRIM28; however, its prognostic value in breast cancer (BC) remains unclear. In the present study, the expression of TRIM28 was identified to be significantly higher in cancerous compared with healthy tissue samples. Furthermore, it was demonstrated that TRIM28 expression was significantly correlated with several clinicopathological characteristics of patients with BC, such as p53 mutation, tumor recurrence and Elston grade of the tumor. In addition, a protein-protein interaction network was created to illustrate the interactions of TRIM28 with other proteins. The prognostic value of TRIM28 in patients with BC was investigated using the Kaplan-Meier Plotter database, which revealed that high expression of TRIM28 is a predictor of poor prognosis in patients with BC. In conclusion, the results of the present study indicate that TRIM28 provides a survival advantage to patients with BC and is a novel prognostic biomarker, in addition to being a therapeutic target for the treatment of BC.

show abstract

Section: Discussionmentioning

confidence: 99%